Clinical Trial Update: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Open-label phase 1/2 trial of the JAK inhibitor INCB052793 in patients with advanced solid tumors; study terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignancies
• Solid Tumors

Drugs mentioned

• INCB052793 (INCB052793)

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors, Advanced Malignancies | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-04-17